An observational study in Intensive Care Unit (ICU) Patients and Metastatic Cancer, sponsored by University Hospital, Brest. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by University Hospital, Brest · Observational
The aim of our study is to optimise the interaction between oncologists and resuscitators to improve decision-making regarding the admission of patients with metastatic solid cancers to the ICU.
The study is structured into two successive stages. The first stage involves a retrospective descriptive analysis of patients with metastatic solid cancer admitted to the ICU, to enable comparison with centres that have already documented this subject.
The second stage involves personalised interviews with medical staff working in both the oncology department and the intensive care unit.
In the vast majority of cases, there is no cure for metastatic solid cancer. As a result, the question of end of life is very often present.
End of life may be linked to the aggressiveness of the disease, to therapeutic damage, but also to an independent acute event that may occur during the course of oncology care.
This explains why the question of resuscitation management comes into play in the care of our oncology patients.
The literature shows that one in 7 patients admitted to intensive care in Europe has a history of cancer, and that 5 to 10% of cancer patients will require intensive care during their course of treatment.
The therapeutic advances brought about by immunotherapy in the first instance, followed by targeted therapies in a second phase, have considerably altered the prognosis of patients with solid cancers, including the most aggressive cancers.
However, given the poor prognosis of these diseases, having metastatic cancer continues to hinder a patient's possible admission to the intensive care unit.
The second most common reason for refusing admission to the ICU is having cancer.
Yet the post-ICU mortality rate for cancer patients is identical to that of the entire ICU patient group.
Various scores have been used to determine the 'right' criteria for ICU admission for patients with metastatic solid cancers.
Nevertheless, nothing appears to be more effective than communication between oncologists and intensive care physicians, particularly since the prognosis of patients with advanced cancers is still a subject of interdisciplinary discussion.
Various scores have attempted to establish the 'right' criteria for admitting patients with metastatic solid cancers to intensive care.
However, nothing appears more effective than discussions between oncologists and resuscitators, particularly given that the prognosis of patients with advanced cancers is still a topic of interdisciplinary debate.
Indeed, the decision to admit a patient with metastatic cancer to an intensive care unit appears to raise ethical, medical and organisational issues.
Bearing this in mind, and given the numerous studies already conducted in this area, we thought it would be interesting to examine the relationship between oncology and intensive care units.
To study the interactions between intensive care physicians and oncologists and identify areas for improvement in patient care, we devised a two-stage approach.
First, we conducted personalised semi-structured interviews with doctors from the medical oncology department (oncologists, organ specialists and general practitioners) and doctors from the intensive care unit. This allowed us to identify the obstacles that each speciality faces when admitting a patient to the intensive care unit. This would enable us to deduce the elements essential for reaching an agreement on admitting a patient to the intensive care unit (Stage 1).
Secondly, we will review practices at Brest University Hospital (and possibly other centres that might be interested in our work) and compare them with data in the literature to see if our decisions are similar to those made in other centres that have already documented the subject (Stage 2).
3,564 studies on the registry are indexed under Neoplasm Metastasis; 875 are open to participants now.
This study's planned enrollment of 139 is above the median of 120 across 604 observational studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →University Hospital, Brest is the lead sponsor of 600 studies on the registry; 135 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ICU patients with metastatic solid cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Descriptive analysis
The descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required.
Frequency of reason for admission to intensive care unit
Analysis of the reason for admission to intensive care unit
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Protective and risk factors
Protective and risk factors for returning home within 3 months
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Survival at 1 month and 3 months
Survival at 1 month and 3 months from admission to intensive care unit
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Risk factors for survival in intensive care
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Criteria for ICU admission of patients
Identification and categorization of major decision criteria reported by physicians for ICU admission of patients with metastatic solid cancer
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available beginning three years and ending fifteen years following the final study report completion
Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.